H.C. Andersen Bio Pharma ApS: Financial statements 2020
CVR: 38683462
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
H.C. Andersen Bio Pharma ApS (CVR 38683462) has filed annual accounts for 2020. In 2020, the company reported revenue of DKK 1,560 and a net result of DKK -111,890 compared with DKK -12,425 the year before. The profit margin was -7,172.4%. Equity in the 2020 report amounted to DKK -281,035.
- Revenue
- DKK 1,560
- Gross Profit
- DKK -110,702
- Profit/Loss
- DKK -111,890
- Equity
- DKK -281,035
- Total Assets
- DKK 46,838
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 2 t. | -111 t. | -112 t. | -281 t. | - |
| 2019 | - | -11 t. | -12 t. | -169 t. | - |
| 2018 | 0 | -190 t. | -191 t. | -157 t. | - |
Official annual report
How creditworthy is H.C. Andersen Bio Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
H.C. Andersen Bio Pharma ApS has published its annual report for 2019. Gross profit came to DKK -11,237, and the net result was DKK -12,425.
About H.C. Andersen Bio Pharma ApS
H.C. Andersen Bio Pharma ApS was a Danish company of the type Anpartsselskab based in København S, founded in 2017. The company has been dissolved on 24 July 2026. The company was registered under the industry Detailhandel med andre nye varer. The company was previously named H. C. Andersen Emeren Group ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,673 compared with DKK -20,418 the year before. Equity in the 2025 report amounted to DKK -312,718.